Tobacco Cessation Toolkit

Summary of Tobacco Cessation Pharmacotherapy – Non-Nicotine

This resource includes summary charts for use in providing non-Nicotine Replacement Therapy pharmacotherapy.

Bupropion SR

Cost: \$2 to \$3 per day	Dosage: 150 mg SR tablets
 Approved Indications Indicated as smoking cessation treatment in conjunction with behavioural modification. Also approved for use in combination with nicotine replacement therapy. Prior to deciding to prescribe a non-nicotine treatment, thorough consideration should be given to the treatment option of nicotine replacement therapy alone. 	 Dosing Starting one to two weeks prior to the target quit date: 150 mg in the morning for three days, followed by 150 mg twice daily, with dosages at least eight hours apart. Taken for 7 to 12 weeks; up to six months can be considered post-quit.
Labelled Dressutions/Indiastions	

Labelled Precautions/Indications

Pregnancy

- Pregnant women should be encouraged to quit without medication.
- Bupropion has not been shown to be effective for tobacco cessation in pregnant women.
- Bupropion has not been evaluated in breastfeeding patients.
- Bupropion is an FDA pregnancy Class C agent.

Cardiovascular disease

• Generally well-tolerated; occasional reports of hypertension.

Seizure risk

- Contraindicated in history of seizures or eating disorders, with concurrent use of another form of bupropion, or use of a MAO inhibitor in the past 14 days.
- Extreme caution in those with risk factors for seizures, including:
 - excessive alcohol use
 - concurrent drug abuse
 - history of head trauma, CNS tumour
 - presence of severe hepatic impairment
 - use of concomitant medications that lower seizure threshold (e.g., antipsychotics, antidepressants, lithium, amantadine, theophylline, systemic steroids, quinolone antibiotics, antimalarials)
 - use of over-the-counter stimulants or anorectics
 - diabetes treated with oral hypoglycemics or insulin

Psychiatric warnings

- Agitation-type events have been reported in both pediatrics and adults, of severe agitationtype adverse events coupled with self-harm or harm to others.
- The agitation-type events include akathisia, agitation, disinhibition, emotional lability, hostility, aggression and depersonalization.




Tobacco Cessation Toolkit | 2

• In some cases, the events occurred within several weeks of starting treatment.

Clinical monitoring for psychiatric symptoms is recommended.

Varenicline

Cost: \$3.50 to \$4.50 per day	Dosage: 0.5 mg,1 mg
Approved Indications	
• Smoking-cessation treatment in adults in conjunction with smoking-cessation counselling. <i>Can be used in combination with bupropion.</i>	
Dosing	
between Weeks 2 and 5)Gradual Quit approach: The patient starts taking 12 weeks of treatment. The patient should grad	
 Dosing 0.5 mg daily for three days, then 0.5 mg twice dail The dosage may be increased to 1 mg twice da be effective. The choice of dosing regimen from day 8 onwar patient preference. 	ily on day eight, but 0.5 mg twice daily may also
 Duration of Treatment Fixed Quit and Flexible Quit Approaches: For p the end of 12 weeks, an additional course of 12 considered. 	atients who have successfully stopped smoking at weeks treatment with varenicline may be
Gradual Quit: Patients who follow the gradual quit varenicline for 24 weeks.	approach (12 week) should be treated with
Labelled Precautions/Indications	
 2017. The need for ongoing assessment of monitorin not typical for the patient remains during any que psychiatric disorders given that these changes Psychiatric warnings remain in the product monitorial product monitorial disorders given that the product monitorial disorders are also be assessed as the product monitorial disorders are also be as the product monitorial disorders are also be assessed as the product monitorial disorders are also be as the product mon	and most recently by Health Canada in February g for any changes in behavior or thinking that are uit attempt for patients with or without a history of can occur with or without medication use.





including anxiety, psychosis, mood swings, depressed mood, agitation, aggression, hostility, changes in behavior or thinking, suicidal ideation, suicidal behavior and suicide, as well as worsening of pre-existing psychiatric disorder (previously diagnosed or not). Not all patients had stopped smoking at the time of onset of symptoms, and not all patients had known pre-existing psychiatric illness, or were using concomitant CNS drugs.

- Recommendations: Clinicians should be aware of the possible emergence of serious neuropsychiatric symptoms in patients attempting to quit smoking, with or without treatment.
- Pre-existing Psychiatric Disorder or Symptoms:
 - Smoking cessation, with or without pharmacotherapy, has been associated with exacerbation of underlying psychiatric illness (e.g. depression, anxiety). Patients with a history of psychiatric symptoms should be monitored for worsening or new symptoms when attempting to quit smoking, regardless of how well controlled symptoms may be when starting smoking cessation treatment. Patients should be instructed to report strongly a typical and concerning symptoms to their healthcare provider, so that dose adjustments of psychiatric medications or varenicline may be considered.

General

• Patients should be informed that if they experience thoughts, moods or behaviours that are strongly atypical and concerning while on smoking-cessation medication, including varenicline, the medication should be discontinued immediately, with urgent medical help sought as needed, and the symptoms reported to their healthcare provider.

Cardiovascular disease

• Patients should be advised to notify a health-care provider of any new or worsening symptoms of cardiovascular disease.

Pregnancy

- Pregnant women should be encouraged to quit without medication.
- Varenicline has not been shown to be effective for tobacco cessation in pregnant women.
- Varenicline is an FDA pregnancy Class C agent.
- Varenicline has not been evaluated in breastfeeding patients.

Renal impairment

- Caution for patients with significant renal impairment (creatinine clearance < 30 ml per min) or who are on dialysis.
- Doses should be reduced for these patients.

Activities

• May experience impairment of the ability to drive or operate heavy machinery.

